Sign in Subscribe
Children

Long-term Outcomes of HIV-1 Treatment with Broadly Neutralizing Antibodies in Children

Strategic Insights

— 1 min read

Researchers from the Harvard University T.H. Chan School of Public Health have reported on the long-term outcomes of children treated with broadly neutralizing antibodies (bNAbs) for HIV-1. In a study published in the Clinical Infectious Diseases journal, the team investigated the use of dual bNAbs as an alternative to standard antiretroviral treatment (ART) in children living with HIV-1. The study, known as the Tatelo Study, aimed to determine the long-term impact of bNAbs on virologic, immunologic, and clinical outcomes in children.

Key Takeaways:

  • The study enrolled 25 children who received bNAb-only treatment for 24 weeks and were followed for an additional 72 weeks.
  • At the end of the 24-week treatment period, all 25 children transitioned to dolutegravir-based ART, with three children experiencing a single episode of HIV-1 RNA above 40 copies/mL.
  • No Grade 3 or 4 events or deaths were reported during the 96-week follow-up period.
  • Absolute CD4 cell counts remained stable at 96 weeks post-bNAb intervention (Median: 1130 cells/mm3, IQR: 840, 1249 cells/mm3).
  • Clinical biomarkers (serology, qualitative HIV DNA) were stable, with only 8 (32%) participants having detectable intact provirus at last available sampling.
  • The study found no long-term impact on safety, clinical, immunologic, or virologic outcomes after bNAb-only treatment, including for children who rebounded during the intervention.

Statistics:

  • 25 children participated in the study.
  • 3 children experienced a single episode of HIV-1 RNA above 40 copies/mL.
  • 8 (32%) participants had detectable intact provirus at last available sampling.
  • Absolute CD4 cell counts remained stable at 96 weeks post-bNAb intervention (Median: 1130 cells/mm3, IQR: 840, 1249 cells/mm3).
  • The median HIV-1 DNA in PBMCs was 0.39 log10 (range 0.1 to 3.8 log10) copies/106 cells.

Sources:

  • Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study. Clinical Infectious Diseases, 2025.
  • AIDS Weekly. October 27, 2025; p 78.

Read more